牛牛AI助理已提取核心訊息
On February 14, 2024, Ginkgo Bioworks Holdings, Inc. reported an amendment to the Schedule 13D filing by Jason Kelly, indicating a change in his ownership stake. The amendment, which is the third of its kind following previous filings, reflects a decrease in Kelly's percentage of Class A Common Stock ownership due to 'sell-to-cover' transactions to meet tax withholding obligations and sales under Rule 10b5-1 compliant plans. As of the amendment date, Kelly beneficially owns 85,752,333 shares, representing 5.0% of the company's Class A Common Stock, a reduction from his prior holdings. This includes both Class A and Class B shares, with the latter convertible to Class A on a one-to-one basis. The filing also marks an exit for Kelly as he ceases to be the beneficial owner of more than five percent of Ginkgo Bioworks' outstanding Class A shares. The transactions leading to this amendment occurred between December 20, 2023, and January 4, 2024, with sales executed through open market transactions at varying prices.
On February 14, 2024, Ginkgo Bioworks Holdings, Inc. reported an amendment to the Schedule 13D filing by Jason Kelly, indicating a change in his ownership stake. The amendment, which is the third of its kind following previous filings, reflects a decrease in Kelly's percentage of Class A Common Stock ownership due to 'sell-to-cover' transactions to meet tax withholding obligations and sales under Rule 10b5-1 compliant plans. As of the amendment date, Kelly beneficially owns 85,752,333 shares, representing 5.0% of the company's Class A Common Stock, a reduction from his prior holdings. This includes both Class A and Class B shares, with the latter convertible to Class A on a one-to-one basis. The filing also marks an exit for Kelly as he ceases to be the beneficial owner of more than five percent of Ginkgo Bioworks' outstanding Class A shares. The transactions leading to this amendment occurred between December 20, 2023, and January 4, 2024, with sales executed through open market transactions at varying prices.
2024年2月14日，Ginkgo Bioworks Holdings, Inc.報告了傑森·凱利對附表13D申報的修正案，表明其所有權發生了變化。該修正案是繼先前申報之後的第三次此類修正案，反映了凱利在A類普通股所有權中所佔百分比的下降，這是由於爲履行預扣稅義務和根據第10b5-1條的計劃進行的銷售而進行的 “賣出到封面” 的交易。截至修訂日，凱利實益擁有85,752,333股股票，佔公司A類普通股的5.0％，比他之前持有的有所減少。這包括A類和B類股票，後者可以一對一地轉換爲A類股票。該文件還標誌着凱利退出，因爲他不再是Ginkgo Bioworks已發行A類股票5％以上的受益所有人。導致該修正案的交易發生在2023年12月20日至2024年1月4日之間，通過公開市場交易以不同的價格進行銷售。
2024年2月14日，Ginkgo Bioworks Holdings, Inc.報告了傑森·凱利對附表13D申報的修正案，表明其所有權發生了變化。該修正案是繼先前申報之後的第三次此類修正案，反映了凱利在A類普通股所有權中所佔百分比的下降，這是由於爲履行預扣稅義務和根據第10b5-1條的計劃進行的銷售而進行的 “賣出到封面” 的交易。截至修訂日，凱利實益擁有85,752,333股股票，佔公司A類普通股的5.0％，比他之前持有的有所減少。這包括A類和B類股票，後者可以一對一地轉換爲A類股票。該文件還標誌着凱利退出，因爲他不再是Ginkgo Bioworks已發行A類股票5％以上的受益所有人。導致該修正案的交易發生在2023年12月20日至2024年1月4日之間，通過公開市場交易以不同的價格進行銷售。
有用
沒用